HIV replication in the human body requires that specific viral RNAs be packaged into progeny virus particles. A new study has found how a small difference in the RNA sequence can allow the viral RNA to be packaged for replication, creating potential targets for future HIV treatments.
Transgender men face significant health and social disparities, including barriers to health care, research, and essential HIV-related conversations with their health care providers. That is why Paige Wermuth, PhD, MPH, assistant professor in the Department of Management, Policy, and Community Health, and graduate student Lou Weaver of The University of Texas Health Science Center (UTHealth Houston) School of Public Health are launching a pilot project to examine and develop communication materials for trans men and their health care providers regarding HIV prevention.
While the rapid development of effective vaccines has helped combat the COVID-19 pandemic, key communities – especially people who are living with HIV – remain disproportionately impacted, and are at higher risk of severe disease and death. Finding an effective HIV vaccine is critically important, and to that end, the HIV Vaccine Trials Network (HVTN) is launching an expanded Faith Initiative that will help advance the work of finding a cure.
The National Institute of Allergy and Infectious Diseases awarded researchers at the Duke Human Vaccine Institute a contract that enables it to compete for projects advancing investigational vaccines to production for use in early clinical trials.
A highly anticipated clinical trial in eight sub-Saharan countries is the first to specifically evaluate the efficacy of a COVID-19 vaccine in people living with HIV, including those with poorly controlled infections. It also is the first study to evaluate the efficacy of vaccines – in this case, Moderna mRNA-1273 – against the omicron variant of SARS-CoV-2, the virus that causes COVID-19.
The University of Texas at El Paso will develop a sustainable public health intervention to suppress human immunodeficiency virus (HIV) in people who use drugs in the El Paso-Ciudad Juárez border region. The initiative will be funded by a $3 million grant from the National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA).
Among HIV-positive black and Latino men who have sex with men, the use of methamphetamine combined with intimate partner violence may increase the risk for developing chronic diseases such as cardiovascular disease and other disorders.
Dec. 1, 2021— People living with HIV experience more severe outcomes and have higher comorbidities from COVID-19 than people not living with HIV, according to the 2020 UNAIDS Global Update. In mid-2021, most people living with HIV did not have access to COVID-19 vaccines. This World AIDS Day, the Forum of International Respiratory Societies (FIRS), of which the American Thoracic Society is a founding member, is calling on governments, health advocates and non-government organisations to strengthen their response to AIDS and COVID-19 by making COVID-19 vaccines more accessible worldwide.
The Bronx is home to more than 27,000 people living with HIV, the majority of whom are Black or Hispanic men. People living with HIV have an increased risk for depression and substance use, which in turn can make adhering to daily antiviral treatments difficult, negatively impacting both quality of life and overall health.
Now, the National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine and Montefiore Health System two five-year grants totaling $7.6 million to study the structural and chemical changes in the brain of people living with HIV, depression, and cannabis use disorder.
A new study published today reveals systematic biases among primary and HIV care providers about people who inject drugs and how those biases may impact access to pre-exposure prophylaxis (PrEP), a preventive, prescription-based medication that significantly reduces the risk of HIV infection through sexual behavior and injection practices.
Neuroimaging study reveals potential brain mechanism underlying chronic neuropathic pain in individuals with HIV. Findings may guide new clinical treatments targeting patients’ expectations for pain relief.
The Rutgers School of Public Health and the Mason Gross School of the Arts have launched a collaboration to support community-engaged, arts-integrated research projects that will result in performances or productions of art.
Thanks to a new $16 million, five-year grant from the National Institute on Drug Abuse of the National Institutes of Health, Case Western Reserve University is launching a multi-institutional research effort dedicated to deepening understanding of the relationship between substance use and HIV.
A new trial by UC San Diego Health infectious disease specialist Maile Young Karris, MD, will use longitudinal questionnaires and qualitative interviews to assess the impact of living in an interconnected virtual village on the loneliness known to afflict older people with HIV.
Armed with a novel strategy they developed for bolstering the body’s immune response, scientists at Albert Einstein College of Medicine have successfully suppressed HIV infections in mice—offering a path to a functional cure for HIV and other chronic viral infections. Their findings were published today in the Journal of Clinical Investigation.
In recent years, crisis pregnancy centers (CPCs) have begun to offer some STI and HIV services, but new research from the University of Georgia suggests that these services may actually be hurting public health efforts to prevent and treat these infections.
Wistar is proud to announce Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH); Jane Shull, chief executive officer of Philadelphia FIGHT; philanthropist Ken Nimblett; Philadelphia Foundation and the Robert I. Jacobs Fund; and Philadelphia FIGHT will be honored at the Wistar Legacy Awards, a celebration of 25 years of continuous HIV research collaboration on Thursday, October 28 from 5:30 to 7:45 p.m.
A nationwide team of researchers, led by scientists at University of Utah Health and The Rockefeller University, has determined how a genetic mutation found in mice and monkeys interferes with viruses such as HIV and Ebola. They say the finding could eventually lead to the development of medical interventions in humans.
Researchers at the Uniformed Services University of the Health Sciences (USU) and Université de Montréal, Canada have discovered a way to potentially eliminate HIV-1 infection in infected individuals by using a new type of antibody-based therapeutics, according to a new study published Sept. 29 in mBio.
The Association of Nurses in AIDS Care (ANAC) honors research led by Anne Teitelman, PhD, FNP-BC, FAANP, FAAN, Associate Professor Emerita in Penn Nursing’s Department of Family and Community Health, as the 2021 JANAC (Journal of the Association of Nurses in AIDS Care) Article of the Year.
A primary analysis of an experimental HIV vaccine regimen being studied in a high-incidence population of young women in sub-Saharan Africa found the experimental vaccine did not provide sufficient protection against HIV infection.
Researchers at Albert Einstein College of Medicine and the City University of New York Graduate School of Public Health and Health Policy (CUNYSPH) have been awarded a five-year, $14.5 million grant from the National Institutes of Health (NIH) to continue leading and expand their research on HIV treatment and care in five Central African nations.
Rutgers School of Public Health assistant professor, Stephanie Shiau, has received a Career Development Award from the National Institute on Drug Abuse, part of the National Institutes of Health, to study the implications of opioid prescription use among older adults living with HIV.
People who are HIV positive and living in high tuberculosis-transmission regions of the world are much more likely to finish a TB-prevention regimen lasting just three months – half as long as the standard treatment, a large clinical trial in Africa has found.
A team led by Dan H. Barouch, MD, PhD, has been awarded $4.9 million in annual funding over the next five years to find a cure for HIV. Barouch was one of ten primary investigators to receive a 2021 National Institutes of Health (NIH) Martin Delaney Collaboratories for HIV Cure Research award, which aims to expedite human immunodeficiency virus (HIV) cure research by bringing together research partners in academia, government, the private sector and the community; coordinating complex research studies, and mentoring the next generation of HIV cure researchers.
Expert Q&A: Do breakthrough cases mean we will soon need COVID boosters? The extremely contagious Delta variant continues to spread, prompting mask mandates, proof of vaccination, and other measures. Media invited to ask the experts about these and related topics.
More than one-third of U.S. adults with HIV are not virally suppressed. People who are not virally suppressed have lower engagement with HIV care and report more barriers to care, reports a study in the September/October issue of The Journal of the Association of Nurses in AIDS Care (JANAC). The official journal of the Association of Nurses in AIDS Care, JANAC is published in the Lippincott portfolio by Wolters Kluwer.
Wistar announces that the National Institutes of Health granted a five-year, $29.15 million Martin Delaney Collaboratories for HIV Cure Research award to the BEAT-HIV Martin Delaney Collaboratory to advance research towards a cure for HIV-1 Infection by Combination Immunotherapy.
NEWS STORIES IN THIS ISSUE:
- COVID-19 NEWS: Johns Hopkins Medicine Study Shows Vaccine Likely Protects People with HIV
- Johns Hopkins Medicine Documents Stroke Risk in Cardiac Assist Device
- CBD Products May Help People with Epilepsy Better Tolerate Anti-Seizure Medications
A University of Miami Miller School of Medicine biochemistry researcher has found that a nanoparticle drug delivery system can reduce HIV/AIDS viral reservoirs in the brain that normally contribute to neurological problems.
A team of researchers co-led by UCLA Fielding School of Public Health epidemiology professor Dr. Matthew Mimiaga has received more than $5.2 million in grants from the U.S. National Institutes of Health (NIH) to develop and test interventions in the U.S. and Brazil.
University of Maryland School of Medicine (UMSOM) Professor of Diagnostic Radiology & Nuclear Medicine, Linda Chang, MD, MS, received the National Institute on Drug Abuse (NIDA) 2021 Avant Garde Award (DP1) for HIV/AIDS and Substance Use Disorder Research — a National Institutes of Health (NIH) Director’s Pioneer Award.
New biomarkers that predict HIV remission after antiretroviral therapy (ART) interruption are critical for the development of new therapeutic strategies that can achieve infection control without ART, a condition defined as functional cure. Wistar Scientists have identified metabolic and glycomic signatures in the blood of a rare population of HIV-infected individuals who can naturally sustain viral suppression after ART cessation, known as post-treatment controllers. T
International organizations and countries around the world are working to eliminate HIV/AIDS by 2030. To reach this goal, new approaches are needed—particularly among difficult-to-reach groups such as people who inject drugs (PWID), who are 30 times more likely to contract HIV/AIDS compared with the general population.